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Abstract
Background: RNA based antiviral approaches against HIV-1 are among the most promising for
long-term gene therapy. These include ribozymes, aptamers (decoys), and small interfering RNAs
(siRNAs). Lentiviral vectors are ideal for transduction of such inhibitory RNAs into hematopoietic
stem cells due to their ability to transduce non-dividing cells and their relative refractiveness to
gene silencing. The objective of this study is to introduce an HIV-1 Tar aptamer either alone or in
combination with an anti-CCR5 ribozyme into CD34+ hematopoietic progenitor cells via an HIV-
based lentiviral vector to derive viral resistant progeny T cells and macrophages.
Results: High efficiency and sustained gene transfer into CD34+ cells were achieved with lentiviral
vector constructs harboring either Tar decoy or Tar decoy in combination with CCR5 ribozyme.
Cells transduced with these constructs differentiated normally into T-lymphocytes in vivo in thy/liv
grafts of SCID-hu mice, and into macrophages in vitro in the presence of appropriate growth factors.
When challenged in vitro, the differentiated T lymphocytes and macrophages showed marked
resistance against HIV-1 infection.
Conclusions: Viral resistant transgenic T cells and macrophages that express HIV-1 Tar aptamer
either alone or in combination with an anti-CCR5 ribozyme could be obtained by lentiviral gene
transduction of CD34+ progenitor cells. These results showed for the first time that expression of
these anti-HIV-1 transgenes in combination do not interfere with normal thymopoiesis and thus
have set the stage for their application in stem cell based gene therapy for HIV/AIDS.
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Background
Human T lymphocytes and macrophages are the major
host cells for HIV-1 replication. The initial infection is
established by macrophage tropic viruses (R5) that use the
chemokine receptor CCR5 and CD4 to gain entry into a
susceptible host cell. During the later stages of the disease,
T-cell tropic viruses (X4) that use CXCR4 as a coreceptor
predominate [1,2]. Since HIV-1 coreceptors play a key role
during the early viral-cell interactions, they are attractive
targets for many antiviral approaches. A 32-base pair dele-
tion in the CCR5 gene found in a segment of the normal
European and North-American population rendered their
macrophages resistant to infection by R5-tropic HIV-1 [3].
Since these individuals lacking a functional CCR5 are
apparently normal, this gene has been targeted by many
investigators to confer HIV-1 resistance. Using MuLV vec-
tors for gene delivery, ribozymes or DNA-enzymes tar-
geted against CCR5 were previously shown to inhibit HIV-
1 entry both in vitro and in vivo in a SCID-hu mouse model
[4-6]. Efficacy of siRNAs in down regulating the CCR5
coreceptor and thereby preventing HIV-1 entry was also
described recently [7,8].
The regulatory proteins Tat and Rev encoded by the viral
genome are indispensable for HIV-1 gene expression and
replication. The Tat protein interacts with the bulged RNA
region of the transactivation response element (Tar),
present at the 5'-end of all HIV-1 transcripts [1]. In the
absence of Tat, only short ineffective transcripts are gener-
ated. Tat is also known to interact with cellular factors like
cyclin T1 and cyclin dependent kinase (Cdk9). Since Tat
plays a critical role in virus replication, it is an ideal target.
Effective inhibition of HIV-1 replication was shown ear-
lier by the use of Tar specific RNA decoys and ribozymes
[9-11]. Moreover, siRNAs directed against Tat were also
found to be highly potent in inhibiting HIV-1 replication
in cultured cell lines and in PBMCs [12,13]. However,
development of viral resistance and generation of escape
mutants are possible obstacles for long range efficacy of
these constructs as exemplified by the recent findings of
Boden et al [14]. These obstacles can be overcome by the
use of combinatorial constructs against multiple targets in
the viral genome as well as cellular targets that assist in
viral infection and replication.
CD34+ hematopoietic progenitor stem cells (HPCs) are
ideal targets for transducing anti-HIV genes as they give
rise to both T cells and macrophages which are the main
viral targets. Most of the previous work with anti-HIV
ribozymes and RNA decoys employed conventional
MuLV derived retroviral vectors to transduce these cells
[5,6,11]. However, the efficiency of gene transduction by
these vectors is relatively low as they are unable to trans-
duce non-dividing cells. In addition, the transgenes car-
ried by these vectors are prone to gene silencing during the
differentiation of end stage cells such as T cells and mac-
rophages [15]. On the contrary, lentiviral vectors appear
not to have these limitations [16,17]. Based on these
advantages, we used the new generation lentiviral vectors
to achieve high level gene transfer and sustained gene
expression. A ribozyme against CCR5 and a Tar aptamer
decoy were previously shown to inhibit HIV-1 in trans-
duced cells [6,18,19]. In previous in vivo studies, MuLV
based conventional retroviral vectors were used. In addi-
tion, it is not known if Tar decoy is effective in in vivo dif-
ferentiated thymocytes. In these studies, our goal is to
determine the utility of these constructs when introduced
into human CD34+ progenitor cells via an HIV-1 based
lentiviral vector to derive HIV resistant differentiated tar-
get cells both in vitro and in vivo. Using an in vitro cell dif-
ferentiation system and in vivo SCID-hu mouse model, we
show that expression of Tar decoy alone or in combina-
tion with an anti-CCR5 ribozyme has no adverse effect on
lineage specific differentiation of CD34+ cells into macro-
phages and T lymphocytes. We also show that the trans-
genic cells display resistance to HIV-1 challenge.
Results
High efficiency transduction of CD34+ cells with lentiviral 
constructs
Early studies using MuLV based retrovirus vectors have
shown the efficacy of aptamers and ribozymes against Tat,
Rev, or envelope in interfering with HIV-1 infection
[5,6,10,20]. Down regulation of CCR5 by the ribozyme
used here and its corresponding inhibitory effect on HIV-
1 infection was described previously [5,6,19]. To further
expand the utility of such inhibitory RNAs, we used a
third generation HIV-1 based self-inactivating vector (Fig.
1) [21] A highly enriched population of human CD34+
cells (>90% pure) were used for vector transductions. A
representative FACS profile of purified CD34+ cells is
shown in Fig. 2A. Transduction efficiency, as determined
by FACS for EGFP at 48 hrs post-transduction, showed
high levels of gene transfer and exceeded 90% for both
U16Tar decoy and Tar-CCR5 vector constructs (Fig. 2,
panel B & C).
Tar and Tar-CCR5Rz vector transduced CD34+ cells 
differentiate normally into mature macrophages
It is not known if lentivirus transduced Tar decoy and Tar-
CCR5Rz, will have any adverse effects on the lineage spe-
cific differentiation of CD34+ cells into different end stage
cells. Our results showed that both control and vector
transduced cells matured normally into erythroid and
myeloid colonies and no significant differences were
observed between their colony forming abilities (data not
shown). To determine if Tar and Tar-CCR5Rz RNA
expressing CD34+ cells can give rise to mature macro-
phages, myeloid colonies were pooled and allowed to dif-
ferentiate into adherent cells in cultures supplementedAIDS Research and Therapy 2004, 1:2 http://www.aidsrestherapy.com/content/1/1/2
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HIV-1 based lentivirus transfer vectors Figure 1
HIV-1 based lentivirus transfer vectors: A, control vector pHIV-7-EGFP with an EGFP reporter gene driven by the CMV pro-
moter. B, HIV-U16Tar (F)-GFP vector with U6 driven Tar decoy. C, HIV-Tar-CCR5 ribozyme vector with U6 driven Tar and 
VA1 driven CCR5 ribozyme [18]. To generate vector viruses, a four-plasmid transfection system was used as described in 
methods.
CD34+ cell purity and transduction efficiency Figure 2
CD34+ cell purity and transduction efficiency: CD34+ cells derived from human fetal liver were purified by immunomagnetic 
beads and assayed by FACS. Percentage purity is indicated in A. Purified CD34+ cells were transduced with HIV-1 Tar (B) and 
Tar-CCR5 ribozyme (C) containing lentiviral vector. Percentages of EGFP positive cells at 48 hrs post-transduction are indi-
cated in panel B and C. Isotype antibody control is shown in each panel (unshaded areas).AIDS Research and Therapy 2004, 1:2 http://www.aidsrestherapy.com/content/1/1/2
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with M-CSF and GM-CSF for a period of 7 days. Results
showed that cells derived from control, vector alone, or
vector expressing transgenes (Tar and Tar-CCR5Rz)
showed similar pattern of CD14 expression (Fig. 3, panel
A1 to A4). The transgenic macrophages were also ana-
lyzed for the levels of EGFP reporter expression. As
expected, the nontransduced cells did not show any EGFP
expression (Fig. 3, panel B1) but cells transduced with
either EGFP vector alone (panel B2) or vector with trans-
genes (panel B3 and B4) were strongly positive (>80%)
for EGFP production. RT-PCR analysis confirmed the
expression of the transgene Tar. Tar specific products of
expected size (125 bp) were detected in both Tar (Fig. 4,
panel A, lane 2) and Tar-CCR5Rz (lane 3) vector trans-
duced macrophages. Control nontransduced macro-
phages, as expected, did not show any specific product
(lane 1). No difference in the amounts of control β-actin
RNA could be seen in the corresponding lanes (Fig. 4,
panel B).
Tar and Tar-CCR5Rz transgenic macrophages resist HIV-1 
challenge
To determine if Tar and Tar-CCR5Rz transduced in vitro
differentiated macrophages resist HIV-1 challenge, they
were infected with R5-tropic HIV-1 Bal strain. Culture
supernatants collected on different days post challenge
were assayed for p24 antigen by ELISA. Compared to
unmanipulated control or EGFP control, both Tar and
Tar-CCR5Rz expressing macrophages showed remarkable
resistance against HIV-1 challenge (Fig. 5). Small amounts
of p24 could be detected on day seven and none at nine
days post infection in Tar and Tar-CCR5Rz transduced
cells.
FACS analysis of transgenic macrophages for the CD14 surface marker and EGFP expression Figure 3
FACS analysis of transgenic macrophages for the CD14 surface marker and EGFP expression: Control and HIV-1 Tar & Tar-
CCR5Rz vector transduced CD34+ cells were differentiated into macrophages in vitro in cytokine medium. Cells were stained 
for the macrophage surface marker CD14 using CD14-PE antibodies. Cells were analyzed by FACS for CD14 and EGFP. Panel 
A: CD14 staining of macrophages. 1, Nontransduced cells; 2, Control EGFP vector transduced; 3, HIV-1-Tar vector trans-
duced; 4, HIV-1-Tar-CCR5Rz transduced. Percent CD14 positive cells are indicated together with isotype staining controls 
(unshaded areas). Panel B: EGFP expression by transduced macrophages. 1, Nontransduced cells; 2, Control EGFP vector 
transduced; 3, HIV-1-Tar vector transduced; 4, HIV-1-Tar-CCR5Rz vector transduced. Percent EGFP positive macrophages 
are indicated.AIDS Research and Therapy 2004, 1:2 http://www.aidsrestherapy.com/content/1/1/2
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Tar and Tar-CCR5Rz transduced CD34+ cells can give rise 
to thymocytes in SCID-hu thy/liv grafts
Human thy/liv grafts in SCID-hu mice provide an ideal
environment for CD34+ cells to mature into thymocytes.
To determine if the lentivirally expressed transgenes Tar
and Tar-CCR5Rz would have any adverse effect on this
differentiation process, thymocytes obtained from SCID-
hu grafts 60–70 days post reconstitution were analyzed
for EGFP expression. All of the four mice (two each with
Tar and Tar-CCR5Rz) that were injected with transduced
CD34+ cells were positive for the presence EGFP express-
ing thymocytes. Of the two mice injected with Tar con-
struct one showed 85% reconstitution levels with the
other being 33%. For the two Tar-CCR5Rz construct
injected mice, the reconstitution levels were 75% and
30% (Fig. 6, panels A and B). Reconstitution levels are
known to vary considerably between mouse to mouse
based on the variable sizes of the grafts injected and pos-
sibly due to the varying numbers of true stem cells present
in the samples injected [22,23]. Since vector transduced
CD34+ cells gave rise to EGFP expressing thymocytes in
SCID-hu grafts, these results suggested that expression of
either Tar or Tar-CCR5Rz RNA did not have any detectable
deleterious effects on the thymopoiesis steps in vivo. FACS
analysis was carried out on biopsied thymocytes by stain-
ing for CD4 and CD8 antigens to evaluate the presence of
different cell subsets. The majority of the thymocytes (75
– 80%) stained positive for CD4 and CD8 (double posi-
tive) consistent with normal thymopoiesis (Fig. 7, panels
B to D). Similar to the control (B), both CD4 and CD8
single positive mature thymocytes are also seen in Tar and
Tar-CCR5Rz transduced thymocytes derived in SCID-hu
grafts (C and D). These data indicated normal develop-
ment of all three thymocyte subpopulations from Tar and
Tar-CCR5Rz transduced CD34+ cells. When these cells
were cultured in vitro for an additional 7 days, a rapid
decline in the number of CD4/CD8 double positive cells
was observed which coincided with a corresponding
increase in single positive mature thymocytes (data not
shown). To determine if the transgenic thymocytes
derived in the SCID-hu mice retained their ability for non-
specific mitogenic stimulation in the presence of IL-2,
they were cultured in the presence of PHA-P for 3 days.
Approximately, a 3-fold increase in the number of thymo-
cytes was observed for both control as well as transduced
cells (data not shown). These cells expressed the chemok-
ine receptor CXCR4, as expected (data not shown).
In vivo derived transgenic thymocytes resist HIV-1 
challenge
To determine if Tar and Tar-CCR5Rz RNA expressing thy-
mocytes display resistance to HIV-1 replication, FACS
sorted EGFP positive cells were challenged with a T-tropic
HIV-1 NL4.3 virus in vitro (Fig. 8). Thymocytes isolated
from both groups of mice (Tar and Tar-CCR5Rz trans-
duced) showed remarkable resistance to HIV-1. In con-
trast, control unmanipulated thymocytes produced large
amounts of virus (~8 fold higher p24 antigen on day 6).
These control cells continued to produce detectable virus
until 25 days post infection (data not shown)
Discussion
The future success of stem cell based gene therapy strate-
gies against HIV-1 infection depends on harnessing novel
interfering genes for in vivo application in humans. This
requires collective utilization of stem cell gene transduc-
tion with novel vectors followed by preclinical evaluation
of gene therapeutic constructs in an in vivo setting. To
achieve this goal, we used lentiviral vectors to transduce
CD34+ cells with a Tar decoy alone or in combination
with an anti-CCR5 ribozyme that down regulates an
essential HIV-1 coreceptor. Tar decoy interferes with an
essential HIV-1 regulatory gene thus inhibiting post-entry
steps of viral replication, whereas the anti-CCR5 ribozyme
helps prevent viral entry. In view of the previously demon-
strated  in vitro high efficacy of aptamers targeted to
different HIV-1 proteins and the high likelihood of these
being exploited for clinical use, it is essential that they be
tested thoroughly in vivo. These experiments mark the first
simultaneous evaluation of these constructs in lentivirally
transduced CD34+ cells both in vitro and in vivo.
RT-PCR detection of Tar RNA in differentiated macrophages Figure 4
RT-PCR detection of Tar RNA in differentiated macro-
phages: Total cellular RNA was extracted from control and 
transgenic macrophages and subjected to RT-PCR using 
primers specific for HIV-1 Tar decoy. A. HIV-1 Tar specific 
amplification (125 bp). 1, control macrophages; 2, HIV-1-Tar 
vector transduced macrophages; 3, HIV-1-Tar-CCR5Rz vec-
tor transduced macrophages. B. β-actin RNA amplified in 
corresponding lanes as controls.AIDS Research and Therapy 2004, 1:2 http://www.aidsrestherapy.com/content/1/1/2
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The use of lentiviral vectors permitted higher levels of
gene transfer (>90%) into CD34+ cells with both of the
constructs as assayed by EGFP expression. Two rounds of
transduction with a highly concentrated VSV-G pseudo-
typed vector helped achieve high levels of gene transfer.
Cells continued to express EGFP throughout the experi-
mental period when cultured in vitro in the presence of
cytokines and growth factors, and as long as 70 days in
vivo  in SCID-hu mice. The self-inactivating lentiviral
vector employed here incorporated two important cis ele-
ments, namely a flap region and a WPRE element, to
achieve high levels of EGFP expression [21]. Additionally,
to minimize promoter interference, EGFP reporter, Tar,
and CCR5 ribozyme genes were placed under the control
of three different promoters namely, CMV, U6 and VA1
respectively [18]. Based on the high levels of gene transfer
and sustained expression obtained, lentiviral vectors are
highly suitable for gene transfer of RNA decoys and
ribozymes.
CD34+ cells can be differentiated into myeloid, erythroid,
and macrophage cell progeny in the presence of appropri-
ate growth factors in vitro, and into mature T lymphocytes
in vivo in SCID-hu mice [6,23]. In vitro CFU assays yielded
similar levels of differentiated erythroid and myeloid col-
onies, and in long term culture with cytokines, more than
90% of cells matured into macrophages and expressed
normal levels of CD14. Remarkably, EGFP production
also remained very high (>80%) in transgenic macro-
phages. Thus lentivirus mediated Tar and Tar-CCR5Rz
transgene expression did not adversely interfere with the
differentiation of CD34+ cells into different lineages
including macrophages. In in vivo experiments with SCID-
hu mice, cell biopsies analyzed 60 to 70 days post engraft-
ment showed that both Tar and Tar-CCR5Rz transduced
progenitor cells matured into T-lymphocytes. During the
normal course of thymopoiesis, the T cell precursors ini-
tially give rise to CD4 and CD8 double positive immature
cells followed by subsequent end stage maturation into
HIV-1 challenge of differentiated macrophages Figure 5
HIV-1 challenge of differentiated macrophages: HIV-1 Tar, Tar-CCR5Rz and control EGFP vector transduced and unmanipu-
lated control CD34+ cells were allowed to differentiate into macrophages in vitro. Later, they were challenged with a macro-
phage tropic HIV-1 strain BaL. Viral supernatants were collected at different times post-infection and assayed for p24 antigen 
by ELISA. Values represent averages of duplicate cultures.AIDS Research and Therapy 2004, 1:2 http://www.aidsrestherapy.com/content/1/1/2
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single positive CD4 and CD8 cells [24]. It is possible that
transgene expression may selectively alter maturation of
different cell subsets. Our results showed the presence of
all three thymocyte subsets in grafts reconstituted with
transduced cells when compared to control cells. Addi-
tionally, when the transgenic thymocytes were sorted and
cultured  in vitro, the levels of immature thymocytes
declined rapidly with a corresponding increase in single
positive CD4 and CD8 cells demonstrating their capacity
to mature. Collectively, this data established that
transduced CD34+ progenitor cells can differentiate nor-
mally into mature macrophages and thymocytes thus
indicating no apparent toxicity of these constructs on lin-
eage specific differentiation.
Viral challenge experiments demonstrated that both Tar
and Tar-CCR5Rz RNA expressing mature T-lymphocytes
and macrophages are remarkably resistant to HIV-1
infection. No synergistic effect could be observed with the
combinatorial construct most likely due to the predomi-
nant effect of the Tar decoy itself at the low m.o.i. used
here. However, synergistic effect of the combinatorial con-
struct was demonstrated in previous studies that used a
higher challenge dose [18]. In early studies with similar
constructs using MuLV based retrovirus vectors, [6,20]
viral inhibition was seen up to 2 weeks post challenge in
differentiated thymocytes. However, there was a
significant viral breakthrough by the third week. In con-
trast, with the lentiviral vector delivered constructs
employed here, virus production in both challenged
macrophages and T-lymphocytes remained significantly
lower throughout the three week observation period. This
improved level of protection is likely due to higher levels
of gene transduction and expression, lower levels of
transgene silencing during cell differentiation steps, or a
combination of both. Although the levels of viral inhibi-
tion achieved in transgenic macrophages and T-lym-
phocytes are highly significant, small amounts of viral
production is still detectable. This could be due to sub-
optimal levels of transgene expression in a subpopulation
of cells, or alternatively due to the presence of a small
number of non-transduced cells in culture. Nevertheless,
the above results demonstrated the efficacy of these trans-
genes in a combinatorial setting in a stem cell-based gene
therapy context. The above results paved the way for
exploiting this approach in human clinical trials.
Conclusions
High efficiency transduction and sustained expression of
HIV-1 interfering genes, anti-CCR5 ribozyme and HIV-1
EGFP expression by in vivo derived thymocytes Figure 6
EGFP expression by in vivo derived thymocytes: HIV-1-Tar and Tar-CCR5Rz vector transduced CD34+ cells were injected 
into the SCID-hu mice thy/liv grafts and allowed to differentiate into thymocytes. At ~60 days post-engraftment, the cells were 
harvested and analyzed by FACS for EGFP expression. A. thymocytes from HIV-1 Tar transduced cells. B. thymocytes from 
Tar-CCR5Rz transduced cells. Percent positive cells are indicated. Representative samples from one mouse each are shown.AIDS Research and Therapy 2004, 1:2 http://www.aidsrestherapy.com/content/1/1/2
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Tar aptamer, could be achieved in CD34+ hematopoietic
progenitor cells by using lentiviral vectors. The transduced
progenitor cells differentiated normally into mature thy-
mocytes in vivo in thy/liv grafts of SCID-hu mice and into
normal macrophages in vitro. When challenged with HIV-
1, transgenic cells showed marked resistance against HIV-
1 infection. These results showed for the first time that
expression of these transgenes in combination do not
interfere with normal thymopoiesis and thus have set the
stage for their application in stem cell based gene therapy
for HIV/AIDS.
Methods
Tar decoy and Tar-CCR5Rz containing lentiviral vectors
The design, structure, and in vitro efficacy in cultured cells
of anti-CCR5 ribozyme, Tar decoy, and Tar-CCR5Rz con-
structs were described previously [5,10,18,19]. These
inhibitory RNAs introduced into a third generation self-
inactivating lentiviral vector were used in the present
study [21]. The transfer vector pHIV-7-GFP containing a
CMV driven EGFP reporter gene is depicted in Fig. 1, panel
1A. Two important unique features are the cis-acting
elements, the HIV-1 central flap sequence and the wood-
FACS profiles of thymocyte subsets derived in SCID-hu grafts Figure 7
FACS profiles of thymocyte subsets derived in SCID-hu grafts: To determine the presence of different thymocyte subsets, in 
vivo differentiated cells from SCID-hu grafts were collected and stained for thymocyte markers CD4 and CD8 by using PE and 
FITC conjugated antibodies respectively. The stained cells were analyzed by two color FACS. A, Isotype control. B, thymocytes 
from a control animal; C, thymocytes from a HIV-1 Tar animal; D, thymocytes from a HIV-1-Tar-CCR5Rz animal.AIDS Research and Therapy 2004, 1:2 http://www.aidsrestherapy.com/content/1/1/2
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chuck post-transcriptional regulatory element (WPRE) for
optimal EGFP expression. In the transfer vector pHIV-
U16-Tar-GFP, the Tar decoy under the control of the U6
promoter was positioned upstream of the EGFP reporter
(Fig 1B). In the combinatorial construct pHIV-U16Tar-
CCR5Rz-GFP, the Tar decoy is driven by U6 whereas the
CCR5 ribozyme is under the control of the VA1 promoter
(Fig. 1C).
Production of high titered retroviral vectors
To generate vector stocks, 293T cells were transfected with
15 µg of pCHGP-2 (encodes HIV-1 gag/pol), 15 µg of
transfer vector (pHIV-7 GFP or pHIV-U16 Tar-GFP or
pHIV-U16Tar-CCR5Rz-GFP), 5 µg of pCMV-rev and
pCMV-G each as described previously [23]. Viral superna-
tants were collected at 24, 48 and, 72 hrs post transfection,
pooled, and concentrated by ultracentrifugation [25].
Concentrated virus was resuspended in a small volume
(500 µl) of DMEM containing 10% fetal bovine serum.
The titer of the vector preparation was determined in 293T
cells as described previously and ranged from 1 to 3 × 108
TU/ml. Multiple aliquots were made and stored at -70°C.
Isolation of CD34+ hematopoietic progenitor cells and 
high efficiency vector transduction
Human fetal liver CD34+ hematopoietic progenitor cells
(HPC) were purified by positive selection on a magnetic
column using the Direct CD34 Progenitor Cell Isolation
Kit from Miltenyi Biotech, Gladbach, Germany, as
described in detail earlier [23]. Purified cells were sus-
pended in Iscove's medium supplemented with IL3, IL6,
and human stem cell factor (SCF), each at a concentration
of 100 ng/ml (R & D Systems, Minneapolis, MN) and cul-
tured for 15 hours at 37°C. Vector transductions were car-
ried out in a 12-well tissue culture plate using 2 × 106 cells
at an m.o.i. of 10 to 20 in a final volume of 100 µl of
medium containing 4 µg/ml polybrene. Following trans-
duction, cell aliquots were used for carrying out in vitro
colony forming unit (CFU) assays, generation of macro-
phages, and for reconstitution of human thy/liv grafts in
SCID-hu mice to generate T cells.
CFU assays and generation of macrophages
Control, or vector transduced CD34+ cells were allowed
to differentiate into multiple lineages of erythroid and
HIV-1 challenge of in vivo differentiated thymocytes Figure 8
HIV-1 challenge of in vivo differentiated thymocytes: Vector transduced CD34+ cells were injected into SCID-hu thymic grafts 
and allowed to differentiate. Thymocytes were harvested from two different mice at 60 days post-engraftment. To enrich for 
the EGFP positive cells, they were sorted by FACS (>90% purity). The cells were expanded by culturing in vitro and challenged 
with the T cell tropic HIV-1 NL4-3. On different days post-infection, samples were collected and assayed for p24 antigen. Tar 
1 & 2 and Tar-CCR5Rz 1 & 2 represent data from two different mice.AIDS Research and Therapy 2004, 1:2 http://www.aidsrestherapy.com/content/1/1/2
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myeloid lineages in a semi-solid medium (MethocultTM
GF H4434, Stem cell Technologies, Vancouver, BC, Can-
ada). This medium contains the following components:
1% Methylcellulose in Iscove's MDM, 30% fetal bovine
serum, 1% bovine serum albumnin, 0.1 mM 2-mercap-
toethanol, 2 mM glutamine, 50 ng/ml rh stem cell factor,
10 ng/ml rh GM-CSF, 10 ng/ml rh IL-3, and 3 units/ml rh
erythropoietin. A colony forming unit (CFU) was defined
as having at least 50 cells after 14 days in the above selec-
tive medium. Individual myelomonocytic colonies were
pooled and cultured in DMEM supplemented with 10%
fetal bovine serum, 50 ng/ml M-CSF, and 20 ng/ml GM-
CSF, for a period of 14 days for differentiation into mac-
rophages. Cells were stained for CD14 antigen and ana-
lyzed by FACS to determine macrophage yield.
Reconstitution of SCID-hu grafts with transduced CD34+ 
cells and derivation of T cells
Human fetal thymus and liver tissues were implanted
under the kidney capsule of SCID mice to generate SCID-
hu mice as described earlier [26]. Control and lentivirus
vector transduced CD34+ progenitor cells (1 × 106) were
injected directly into thy/liv grafts for reconstitution. Eight
to ten weeks post reconstitution, thus allowing for T cell
differentiation, the animals were sacrificed and thymo-
cytes were isolated from the grafts. The differentiated thy-
mocytes were cultured in vitro and checked for their ability
to respond to mitogen, PHA-P and interleukin-2. Briefly,
thymocytes were washed once with medium containing
serum and resuspended into Iscove's medium supple-
mented with 10% fetal bovine serum. Approximately 2 ×
106 cells were plated in a 12 well tissue culture plate and
stimulated with PHA-P (4 µg/ml) and IL-2 (10 U/ml) for
three days. Cells were counted after 3 days to determine
expansion.
PCR Detection of Tar RNA
Total RNA was isolated from approximately 1 × 106 con-
trol and transgenic macrophages using Qiagen RNA/DNA
mini kit (Qiagen, Germany) and subjected to RT-PCR as
described before [20]. In each case, a 125 bp DNA frag-
ment is expected. The following primers were used: 1, For-
ward Tar: 5'-GCAATGATGTCGTAATTTGC and 2, Reverse
Tar: 5'-CTTGCTCAGTAAGAATTTTCGTC.
HIV-1 infection of thymocytes
Thymocytes derived from thy/liv grafts of SCID-hu mice
were sorted by FACS to enrich for EGFP expressing cells
(>90% purity). They were later expanded by stimulation
by PHA-P in medium containing serum and IL-2 as
described earlier [6,23]. Approximately 106  cells were
infected with HIV-1 NL4-3 at an m.o.i. of 0.001 in a final
volume of 100 µl for 3 hrs at 37°C. Infected cells were
washed twice with DMEM with 10% fetal bovine serum
and cultured in a 12 well plate for 3 weeks. Supernatants
(0.5 ml) were collected on alternative days with media
replenished in each well. Amounts of virus produced in
cell culture supernatants was measured by HIV-1 p24
ELISA.
HIV-1 challenge of CD34+ cell derived macrophages
Infection with a macrophage-tropic Bal-1 strain of HIV-1
was carried out in a 6 well plate. Approximately 2 × 106
adherent macrophages differentiated in vitro were infected
with Bal-1 virus at an m.o.i. of 0.001 in the presence of 4
µg/ml of polybrene for 6 hours. Thereafter, 3 ml of DMEM
supplemented with 10% serum was added. Supernatants
(0.5 ml) were collected every other day from each well for
3 weeks and stored at -70°C. The levels of virus released
were determined by p24 antigen ELISA.
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